Bronchial asthma is characterized by chronic airway inflammation. Eosinophils are involved in airway inflammation and play crucial roles in asthma. There is accumulating evidence to suggest contributions of cysteinyl leukotrienes (cysLTs) and thromboxane (TX) A 2 to the recruitment of eosinophils into lung in asthmatics. KP-496 is a novel dual antagonist for CysLT receptor type 1 and TXA 2 receptors. The aim of this study was to evaluate the anti-inflammatory effects of KP-496 on Sephadex-induced airway inflammation. Sephadex suspension was intratracheally injected into rats. Amounts of regulated on activation, normal T cell expressed and secreted (RANTES) and eotaxin, and numbers of infiltrating cells in bronchoalveolar lavage fluid were measured 24 and 48 h after Sephadex injection, respectively. KP-496 (30, 100 m mg/head) was intratracheally administered to rats 1 h before and 7 h after Sephadex injection. KP-496 and prednisolone (10 mg/kg, per os) exhibited significant inhibitory effects on infiltration of total cells and eosinophils into lung. Production of RANTES was significantly inhibited by KP-496 and prednisolone. Production of eotaxin was significantly inhibited by prednisolone. KP-496 also inhibited the production of eotaxin, though this effect was not significant. These results demonstrate that KP-496 exhibited the anti-inflammatory effects by inhibiting infiltration of inflammatory cells and productions of RANTES and eotaxin.
Bronchial asthma is characterized by chronic airway inflammation. Eosinophils are involved in airway inflammation and play crucial roles in asthma. Various types of mediators which recruit and activate eosinophils are involved in the development of airway inflammation.
The cysteinyl leukotrienes (cysLTs, including LTC 4 , LTD 4 , and LTE 4 ) which are lipid mediators generated from arachidonic acid are potent bronchoconstrictors. 1) CysLT type1 receptor (CysLT 1 ) antagonists including montelukast, 2) pranlukast, 3) and zafirlukast, 4) exhibit beneficial effects on the clinical symptoms of asthma. In addition to bronchoconstriction, cysLTs are implicated in airway inflammation and induce eosinophil recruitment to the lung. Aerosolized cysLTs elicit recruitment of eosinophils into lung in guinea pigs, which is blocked by CysLT 1 antagonists. 5, 6) It has also been reported that LTD 4 challenge increased the percentage of eosinophils in sputum from asthmatics. 7) CysLT 1 antagonist reduced sputum and mucosal eosinophils in asthmatics. 8, 9) In addition to CysLT 1 antagonists, the thromboxane (TX) A 2 receptor (TP) antagonist seratrodast 10) is available in Japan. TXA 2 is a lipid mediator generated from arachidonic acid. TXA 2 is thought to be an important mediator in the development of asthma because of its potent bronchoconstrictive activity. 11) Moreover, there is accumulating evidence to suggest that TXA 2 is involved in airway inflammation. 12, 13) In asthmatics, seratrodast significantly decreases the number of submucosal eosinophils and concentration of eosinophil cationic protein (ECP) in sputum. 14, 15) Although the mechanism by which cysLTs and TXA 2 induce recruitment of inflammatory cells is not fully clear, these findings suggest contributions of cysLTs and TXA 2 to the recruitment of eosinophils into lung in asthmatics. KP-496 (2-{N-[4-(4-chlorobenzenesulfonylamino)butyl]-N-{3-[(4-isopropylthiazol-2-yl)methoxy]benzyl}sulfamoyl}benzoic acid) is a novel dual antagonist for CysLT 1 and TP. 16 ) Inhaled KP-496 exhibited significant inhibitory effects on immediate airway response (IAR), late airway response (LAR), and airway hyperresponsiveness (AHR). 17) However, anti-inflammatory effect of KP-496 is not investigated.
Sephadex-induced airway inflammation is a convenient model for evaluating the effects of potential anti-inflammatory compounds. Instillation of Sephadex induced significant eosinophil recruitment into lung, which was associated with increased expression of chemokines, cytokines, and lipid mediators. [18] [19] [20] Eosinophils play important roles in airway inflammation, and the C-C chemokines, regulated on activation, normal T cell expressed and secreted (RANTES) and eotaxin, contribute to eosinophil recruitment, survival, and activation. 21, 22) In the present study, we evaluated the anti-inflammatory effects of KP-496 on Sephadex-induced airway inflammation in rats by measuring the recruitment of inflammatory cells into lung and the amounts of RANTES and eotaxin in lung. In the previous study, we evaluated the in vivo antagonistic activities of inhaled KP-496, suspecting that inhalational administration would maximize the pharmacological properties of KP-496. Thus KP-496 was administered intratracheally in the present study. March 25, 2009 150-200 g) were purchased from Charles River Japan, Inc. (Yokohama, Japan). The handling and treatment of the animals were in accordance with the guidelines of the Japanese Association for Laboratory Animal Science (1987) .
MATERIALS AND METHODS

Animals
Drugs and Chemicals A dry powder formulation of KP-496 (KP-496DPI) containing 3 and 10% of KP-496 and vehicle for KP-496DPI were prepared by Kaken Pharmaceutical Co., Ltd. (Tokyo, Japan). Prednisolone (50 mg of watersoluble prednisolone) was purchased from Shionogi & Co., Ltd. (Osaka, Japan). Methylcellulose (MC) was purchased from Nacalai Tesque, Inc. (Kyoto, Japan). Urethane was purchased from Sigma (St. Louis, MO, U.S.A.). Sephadex TM G75S Superfine was purchased from Amersham Biosciences (Uppsala, Sweden).
Drug Administration Vehicle and KP-496DPI were weighed into silicone tubes (1 mg per tube). A compressor (PARI GmbH, Starnberg, Germany) was connected to an air hose and a three-way stopcock. A silicone tube containing the test compound was connected to the other end of the three-way stopcock. A tracheal cannula for intratracheal administration was connected to the silicone tube. Animals were anesthetized with ether and the tracheal cannula was inserted into the trachea from the oral cavity noninvasively. It was confirmed that treatment with ether had no effect on inflammatory cell recruitment and expression of chemokines. The test compound was sprayed by rapidly and fully opening the three-way stopcock connected to the compressor and sending compressed air from the compressor. The amounts of KP-496 administered were 30 mg/head and 100 mg/head, respectively, when 3% and 10% of KP-496DPI were administered. The prednisolone was dissolved with 0.5% MC and administered orally. Vehicle for KP-496 intratracheally (i.t.) and 0.5% MC [per os (p.o.)] were administered in the sham and control groups. KP-496DPI (3 and 10%, i.t.) and 0.5% MC (p.o.) were administered in the KP-496 group (30 mg/head and 100 mg/head group, respectively). Vehicle for KP-496 (i.t.) and prednisolone (10 mg/kg, p.o.) were administered in the prednisolone group. The drugs were administered 1 h before and 7 h after intratracheal administration of Sephadex following the procedures shown below.
Sephadex Injection Sephadex was prepared as a suspension (5 mg/ml) by soaking in saline. Animals were anesthetized with ether and a tracheal cannula, the Surfloflash 18Gϫ2 (Terumo Corporation, Tokyo, Japan), was inserted into the trachea from the oral cavity noninvasively and connected to a 1 ml syringe containing Sephadex, and Sephadex was injected (5 mg/kg, i.t.).
Measurement of Cells
The animals were anesthetized with urethane [1 g/kg, intraperitoneally (i.p.)] and sacrificed 48 h after Sephadex injection. The trachea was exposed and cannulated. The airway lumen was lavaged by flushing with phosphate buffered saline (PBS) (Ϫ) 4 times (4, 5, 6, and 7 ml each), and bronchoalveolar lavage fluid (BALF) was recovered. The BALF was centrifuged (200ϫg) for 10 min at 4°C. The cell pellet was resuspended in 0.5 ml of PBS (Ϫ). Total cell number was counted with a particle counter (CDA-500, Sysmex Corporation, Kobe, Japan). The cytospin preparations were stained with Giemsa, and more than 200 cells were counted to determine the cell differential.
Measurement of RANTES and Eotaxin by EnzymeLinked Immunosorbent Assay (ELISA) The animals were anesthetized with urethane (1 g/kg, i.p.) and sacrificed 24 h after Sephadex injection. BALF was recovered as described above. Supernatant of BALF was concentrated by ultrafiltration (1500ϫg, 390 min, 4°C) using the Centriplus YM-3 (Billerica, MA, U.S.A.). Concentrated sample was dried using a centrifugal evaporator (300 min, 25°C) and dissolved in PBS (Ϫ) to prepare 10-fold concentrated BALF. The amounts of RANTES and eotaxin were measured using ELISA Kit (Biosource Co., Ltd., Camarillo, CA, U.S.A. and R & D Systems, Minneapolis, MN, U.S.A., respectively).
Statistical Analysis The same experiment was conducted twice and the reproducibility of the results was confirmed. In this study, the values of 2nd experiment were expressed as the meanϮS.D. Statistical analysis was performed using one-way analysis of variance followed by Dunnett's multiple range test and Student's t-test, as appropriate. Values at pϽ0.05 were considered significant.
RESULTS
Effects of KP-496 on Inflammatory Cell Recruitment
Numbers of inflammatory cells in BALF were measured 48 h after intratracheal injection of Sephadex. Total cell number and numbers of all types of cells in the control group were significantly increased compared with the sham group (pϽ0.01, Table 1 ). Eosinophils, monocytes/macrophages, neutrophils, and lymphocytes in the control group were increased respectively 615-fold, 2.3-fold, 20.9-fold, and 9.9-fold compared with the sham group. The KP-496 (100 mg/head) group and prednisolone (10 mg/kg) group exhibited significant inhibition of numbers of infiltrating total cells, eosinophils, monocytes/macrophages, and lymphocytes compared with the control group (Fig. 1, Table 1 ). Infiltration of all types of cells except neutrophils was decreased in the KP-496 (30 mg/head) group, though not to significant extents. Fig. 3 ).
Effects of KP-496 on Amounts of RANTES and Eotaxin in BALF The amount of RANTES and eotaxin in
Production of eotaxin was significantly inhibited in the prednisolone group compared to the control group ( pϽ0.01), while the KP-496 (100 mg/head) group exhibited a tendency toward inhibition of production of eotaxin ( pϭ0.080). The amount of eotaxin also decreased in the KP-496 (30 mg/head) group, though not to a significant extent.
DISCUSSION
In the present study, we investigated the effects of KP-496 on Sephadex-induced airway inflammation in rats. KP-496 inhibited the recruitment of inflammatory cells, especially eosinophils, into lung. KP-496 also reduced the amount of RANTES and eotaxin in lung.
Sephadex-induced airway inflammation is characterized by increase in number of eosinophils. The exact mechanism of airway inflammation caused by intratracheal instillation of Sephadex is not clear, but macrophage activation through phagocytosis, mast cell degranulation and T cell activation are thought to be involved in eosinophilic inflammation. 18, 23) The increase in eosinophil numbers is accompanied by increase in amounts of chemokines and Th2 cytokines in lung and AHR. 24, 25) Airway inflammation including eosinophil recruitment and AHR are characteristic features in asthmatics. Chemokines and Th2 cytokines play important role in the development of airway inflammation. It had been demonstrated that the degree of AHR is related to severity of asthma symptoms. 26) Therefore, this model is thought to reflect important aspects of asthma and is useful and convenient for investigation of the anti-inflammatory effects of small compounds. In fact, many groups have investigated the anti-inflammatory effects of small compounds and steroids using this model. 20, [27] [28] [29] The cysLTs are potent eosinophil chemoattractants and promote eosinophil survival. 30, 31) CysLTs also induce upregulation of their own receptor, CysLT 1 , and CysLT 1 antagonist inhibited the up-regulation of CysLT 1 induced by cysLTs. 32, 33) The CysLT 1 antagonistic activity of KP-496 thus contributes to the inhibition of recruitment of eosinophils.
In addition to cysLTs, RANTES and eotaxin are eosinophil activating and chemoattractant chemokines. In fact, numbers of cells expressing eotaxin and RANTES were sig- nificantly increased, and enhanced expression of C-C chemokine receptor 3 (CCR3) was observed in asthmatics. 34, 35) Furthermore, there is a strong relationship between the expression of eotaxin and severity of asthma. 35) It has been reported that cysLTs activate nuclear factor (NF)-k B and induce RANTES production from isolated lung mononuclear cells, which might in turn cause recruitment of eosinophils into the lung.
36) The CysLT 1 antagonists, montelukast and pranlukast, inhibited the activation of NFk B. [36] [37] [38] The CysLT 1 antagonistic activity of KP-496 should thus reduce the production of RANTES by inhibition of NFk B activation and prevent the recruitment of eosinophils into lung.
Interleukin (IL)-5 also plays crucial role in eosinophil activation and survival. In the present study, we did not investigate the effect of KP-496 on IL-5 production. But, it has been demonstrated that CysLTs induced IL-5 production from inflammatory cells and CysLT antagonists inhibited IL-5 production. 33, 39, 40) Additionally, some results suggested that IL-5 and eotaxin might promote the recruitment of eosinophils into lung cooperatively. 41, 42) Thus, it can be expected that CysLT 1 antagonistic activity of KP-496 might contribute to inhibit the recruitment of eosinophils through inhibiting IL-5 production and cooperative action of IL-5 with eotaxin.
It is not clear if TXA 2 has eosinophil chemoattractant activity like cysLTs. However, some groups have reported the involvement of TXA 2 in airway inflammation.
10,12,13) Hoshino et al. 14) reported that administration of seratrodast to asthmatics reduced the number of activated eosinophils in bronchial mucosa and the production of the C-C chemokines RANTES and eotaxin. Although the mechanisms by which TXA 2 induced production of these chemokines are unclear in detail, it has been reported that TXA 2 analogue induced the production of RANTES. 43) Thus, C-C chemokines might be produced in part by direct stimulation via TP, and antagonism by seratrodast and KP-496 of TP might contribute to the inhibition of their production.
These findings and those of previous reports suggest that KP-496 exhibit the anti-inflammatory effects by inhibiting infiltration of inflammatory cells into lung and productions of RANTES and eotaxin. In addition to these results, KP-496 exhibited anti-inflammatory effects on a guinea pig chronic airway inflammation model (manuscript in preparation).
According to the GINA guideline, inhaled corticosteroids (ICS) are the first choice for control of asthma. However, it is known that ICS do not inhibit the production of cysLTs. 44, 45) It has also been reported that CysLT 1 antagonists and a TP antagonist exhibit additive effects with ICS. 46) Moreover, there is some evidence that inhibition of multi-mediators, including KP-496, provides more potent effects on airway obstruction than inhibition of single mediators. 17, 47, 48) It can thus be expected that KP-496 will provide new therapeutic approach and choice such as combination of ICS and KP-496 to asthmatics.
